Immunoassays in Pharmacology and Toxicology

  • V. Marks


Pharmacology is one of the oldest of the medical sciences. For much of its history, however, pharmacology was concerned almost exclusively with pharmacodynamics, i.e. what drugs do to the body — rather than with pharmacokinetics, i.e. what the body does to drugs. This aspect of pharmacology can, to a large extent, be said to date from the studies by Williams on drug metabolism and the appearance of his classic monograph on detoxication mechanisms. Studies on pharmacokinetics were hindered, even in those rare instances in which they might have been considered necessary, by the lack of suitable methods for measuring drugs in biological fluids and for following their metabolism and secretion.


Biological Fluid Therapeutic Drug Monitoring Native Drug Small Laboratory Animal Homogeneous Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marks, V., Lindup, W. E. and Baylis, E. M. (1973). Measurement of therapeutic agents in blood. Adv. Clin. Chem., 16, 47PubMedCrossRefGoogle Scholar
  2. 2.
    Marks, V., Morris, B. A. and Teale, J. D. (1974). Pharmacology. Br. Med. Bull., 30, 80PubMedGoogle Scholar
  3. 3.
    Landon, J. and Moffat, A. C. (1976). The radioimmunoassay of drugs: a review. Analyst, 101, 225PubMedCrossRefGoogle Scholar
  4. 4.
    Butler, V. P. (1975). Drug immunoassays. J. Immunol. Methods, 7, 1PubMedCrossRefGoogle Scholar
  5. 5.
    Mould, G. P., Aherne, G. W., Morris, B. A., Teale, J. D. and Marks, V. (1977). Radioimmunoassay of drugs and its clinical application. Eur. J. Drug Metab. Pharmacol., 4, 171CrossRefGoogle Scholar
  6. 6.
    Marks, V. (1979). New developments in immunoassays for therapeutic drug monitoring. In Schonfield, H., Brockman, R. W. and Hahn, F. E. (eds.) Antibiotics and Chemotherapy, pp. 16–26. ( Basel: Karger )Google Scholar
  7. 7.
    Marks, V., Mould, G. P., O’Sullivan, M. J. and Teale, J. D. (1980). Monitoring of drug disposition by immunoassay. In Bridges, J. W. and Chasseaud, L. F. (eds.) Progress in Drug Metabolism, Vol. 4, ( Chichester: Wiley )Google Scholar
  8. 8.
    Erlanger, B. F. (1973). Principles and methods for the preparation of drug protein conjugates for immunological studies. Pharmacol. Rev., 25, 271PubMedGoogle Scholar
  9. 9.
    Aherne, G. W. and Marks, V. (1979). Radioimmunoassay techniques. In Techniques in Metabolic Research, pp. B215, 1–19. ( Amsterdam: Elsevier )Google Scholar
  10. 10.
    Morris, B. A., Robinson, J. D., Piall, E., Aherne, G. W. and Marks, V. (1974). Development of a radioimmunoassay for morphine having minimal cross-reactivity with codeine. J. Endocrinol, 64, 6 PGoogle Scholar
  11. 11.
    Robinson, J. D., Morris, B. A., Piall, E. M., Aherne, G. W. and Marks, V. (1975). The use of rats in screening of drug protein conjugates for immunoreactivity. In Pasternak, G. A. (ed.) Radioimmunoassay in Clinical Biochemistry, pp. 101–11. ( London: Heyden )Google Scholar
  12. 12.
    Mould, G. P., Stout, G., Aherne, G. W. and Marks, V. (1978). Radioimmunoassay of amitriptyline and nortriptyline in body fluids. Ann. Clin. Biochem., 15, 221PubMedGoogle Scholar
  13. 13.
    Mould, G. P., Clough, J., Morris, B. A., Stout, G. and Marks, V. (1980). Radioimmunoassay of propranolol in plasma. Biopharmaceutics and Drug Disposition. (In press)Google Scholar
  14. 14.
    Vaitukaitis, J., Robbins, J. B., Nieschlag, E. and Ross, G. T. (1971). A method for producing specific antisera with small doses of immunogen. J. Clin. Endocrinol. Metab., 33, 988PubMedCrossRefGoogle Scholar
  15. 15.
    Teale, J. D., Clough, J. M. and Marks, V. (1977). Radioimmunoassay of bleomycin in plasma and urine. Br. J. Cancer, 35, 822PubMedCrossRefGoogle Scholar
  16. 16.
    Kamel, R. S., Landon, J. and Smith, D. S. (1979). Novel 1251-labelled nortriptyline derivatives and their use in liquid phase or magnetizable solid-phase second-antibody radioimmunoassays. Clin. Chem., 25, 1997PubMedGoogle Scholar
  17. 17.
    Al-Bassam, M. N., O’Sullivan, M. J., Gnemmi, E., Bridges, J. W. and Marks, V. (1978). Double-antibody enzyme-immunoassay for nortriptyline. Clin. Chem., 24, 1590PubMedGoogle Scholar
  18. 18.
    Miller, J. N., Lim, C. S. and Bridges, J. W. (1980). Fluorescamine and fluorescein as labels in energy-transfer immunoassay. Analyst, 105, 91CrossRefGoogle Scholar
  19. 19.
    Bastiani, R. J. (1979). The EMIT® system: a commercially successful innovation. In Schonfeld, H., Brockman, R. W. and Hahn, F. E. (eds.) Antibiotics and Chemotherapy, pp. 89–97. ( Basel: Karger )Google Scholar
  20. 20.
    Marks, V. and Teale, J. D. (1979). The radioimmunoassay of cannabinoids: its clinical, pharmacological and forensic applications. In Nahas, G. G. and Paton, W. D. M. (eds.) Marihuana: Biological Effects. Analysis, Metabolism, Cellular Responses, Reproduction and Brain, pp. 81–88. ( Oxford and New York: Pergamon Press )Google Scholar
  21. 21.
    Williams, P. L., Moffat, A. C. and King, L. J. (1978). Combined high-pressure liquid chromatography and radioimmunoassay method for the quantitation of delta-9-tetrahydrocannabinol and some of its metabolites in human plasma. J. Chromatogr., 155, 273PubMedCrossRefGoogle Scholar
  22. 22.
    De Graeve, J. (1980). Some considerations regarding drug determinations in biological fluids with physico-chemical methods. In Siest, G. and Young, D. S. (eds.) Drug Measurement and Drug Effects in Laboratory Health Science, pp. 2–19. ( Basel: Karger )Google Scholar
  23. 23.
    Reiss, W., Brechbuhler, S. and Dubois, J. P. (1979). Rational analysis of drugs in biological fluids with particular reference to the tricyclic antidepressants. In Bridges, J. W. and Chasseaud, L. F. (eds.) Progress in Drug Metabolism, Vol. 3, pp. 115–49. ( Chichester: Wiley )Google Scholar
  24. 24.
    Marks, V. (1979). Clinical monitoring of therapeutic drugs. Ann. Clin, Biochem., 16, 370PubMedGoogle Scholar
  25. 25.
    Richens, A. and Marks, V. (1981). Therapeutic Drug Monitoring ( Edinburgh: Churchill Livingstone )Google Scholar
  26. 26.
    Schneider, R. S., Bastiani, R. J., Leute, R. K., Rubenstein, K. E. and Ullman, E. F. (1974). Use of enzyme and spin-labelling in homogeneous immunochemical detection method. In Mule, S. J., Sunshine, I., Braude, M. and Willette, R. E. (eds.) Immunoassays for Drugs Subject to Abuse, pp. 45–74. ( Cleveland: CRC Press )Google Scholar
  27. 27.
    Wong, R. C., Burd, J. F., Carrico, R. J., Buckler, R. T., Thoma, J. and Boguslaski, R. C. (1979). Substrate-labelled fluorescent immunoassay for phenytoin in human serum. Clin. Chem., 25, 686PubMedGoogle Scholar
  28. 28.
    Aherne, G. W., Marks, V., Morris, B. A., Piall, E. M., Robinson, J. D. and Twycross, R. G. (1975). The measurement of serum morphine levels by radioimmunoassay following oral administration of diamorphine or morphine. Br. J. Pharmacol., 54, 228 pGoogle Scholar
  29. 29.
    Baylis, E. M., Hall, M. S., Lewis, G. and Marks, V. (1972). Effects of renal function on plasma digoxin levels in elderly ambulant patients in domiciliary practice. Br. Med. J., 1, 338PubMedCrossRefGoogle Scholar
  30. 30.
    Juel, R. (1979). The 1978 College of American Pathologists Therapeutic Drug Monitoring Interlaboratory Survey Program. Am. J. Clin. Pathol., 72, 306PubMedGoogle Scholar
  31. 31.
    American Association for Clinical Chemistry (1980). Therapeutic Drug Monitoring: Continuing Education and Quality Control Program. ( Washington: AACC )Google Scholar
  32. 32.
    Marks, V., O’Sullivan, M. J., Al-Bassam, M. N. and Bridges, J. W. (1978). A double antibody enzyme-immunoassay for methotrexate. In Pal, S. B. (ed.) Enzyme Labelled Immunoassay of Hormones and Drugs, pp. 419–28. ( Berlin: De Gruyter )Google Scholar
  33. 33.
    Ngowi, F. (1979). Development of an enzyme immunoassay for measuring 6-alphamethylprednisolone in biological fluids. MSc Thesis, University of SurreyGoogle Scholar
  34. 34.
    Teale, J. D., Clough, J. M., King, L. J., Marks, V., Williams, P. L. and Moffat, A. C. (1977). The incidence of cannabinoids in fatally injured drivers: an investigation by radioimmunoassay and high pressure liquid chromatography. J. Forens. Sci. Soc., 17, 177CrossRefGoogle Scholar
  35. 35.
    Marks, V. and Fry, D. E. (1977). Detection and measurement of drugs in biological fluids: their relevance to the problem of drug abuse. In Glatt, M. M. (ed.) Drug Dependence: Current Problems and Issues, pp. 295–327 ( Lancaster: MTP Press )Google Scholar
  36. 36.
    Morris, D. L., Rawson, D., Ellis, P. B., Hornby, W. E., Schroeder, H. R., Boguslaski, R. C. and Carrico, R. J. (1979). Specific binding assays with a prosthetic group as label. Ann. Clin. Biochem., Suppl. 1, 25Google Scholar
  37. 37.
    Schroeder, H. R., Vogelhut, P.O., Carrico, R. J., Boguslaski, R. C. and Buckler, R. T. (1976). Competitive protein binding assay for biotin monitored by chemiluminescence. Anal. Chem., 48, 1933PubMedCrossRefGoogle Scholar
  38. 38.
    Luster, M. I., Albro, P. W., Chase, K., Clark, G. and McKinney, J. D. (1978). Radioimmunoassay for mono-(2-ethylhexyl) phthalate in unextracted plasma. Clin. Chem., 24, 429PubMedGoogle Scholar

Copyright information

© MTP Press Limited 1981

Authors and Affiliations

  • V. Marks

There are no affiliations available

Personalised recommendations